[ad_1]
At this time, trials of the AstraZeneca vaccine have resumed only in Britain, after the pharmaceutical company announced several days ago that it decided, on a voluntary basis, to suspend the third phase of clinical trials it conducts around the world, including 30 thousand people, on the special experimental vaccine. It is against the disease “Covid-19”, which was developed by his partner, the University of Oxford, after one of the participants in these experiments was infected with “an inexplicable disease”. In this sense, the scientific journal Nature published a report yesterday, in which it stated that some scientists have criticized the sponsors of the clinical trials of the British vaccine for not revealing more information about the reason for stopping the trial previously, and how it was they made their decisions. The University of Oxford and AstraZeneca have yet to release details about the reaction that led to the suspension of the experiment and how the decision was made to resume the studies in the UK. It is also not known whether vaccine trials will also resume in South Africa, Brazil and the United States. The newspaper “New York Times” revealed that “a person familiar with the situation (that is, the condition of the British patient), on condition of anonymity, said that the volunteer had been registered in the phase 2/3 trial, which has its headquarters in the United Kingdom “. “A volunteer in the UK trial was found to have a spinal cord infection (transverse myelitis),” he added. However, the timing of this diagnosis and whether it is directly related to the AstraZeneca vaccine is unclear.
Russian vaccine
Regarding the Russian vaccine “Sputnik-V”, the Russian news agency “TASS” quoted last Saturday the Russian Minister of Health, Mikhail Murashko, that “The first batches of the Russian Corona vaccine were sent to all regions of the world. country, and are expected to be completed. Delivery is until Monday. “The first batches of the vaccine have already been shipped and we are now checking the delivery system so that staff are aware of this,” added Murashko. The Leningrad region will be among the first to receive the vaccine. ” Yesterday, Reuters quoted the head of the Russian sovereign wealth fund, Kirill Dmitriev, which finances the Gamalia Institute of the Russian Ministry of Health that produced the vaccine, that Russia has completed the process of recruiting those willing to participate in the third phase. of experiments in Sputnik-V. And that the number of these reached 55 thousand, while Russia had allocated 40 thousand people for the experience at the beginning. According to “Reuters” also, and according to Russian officials, the preliminary results of the third phase of the experiments, contrary to expectations, will appear at the end of October or November 1 of this year, not in the middle of next year. Keep in mind that the third phase of clinical trials usually takes many months or years to complete.
Only in Great Britain have AstraZeneca vaccine trials been resumed
Corona early warning
In parallel, the newspaper “Washington Post” reported that the University of Arizona in the United States of America managed to overcome a possible outbreak of “Corona”, before it spread, among the more than 300 students who recently moved into residence university. This was done by examining the building’s wastewater for any traces of the virus, to show that the water contained RNA for Corona, just days after the transfer of the students, whose test results were all negative. After that, the university re-examined the 311 residents and housing workers, to find that two students were infected with the virus without showing symptoms, forcing them to quarantine. Former US surgeon Richard Carmona, who is now a professor at the university, said this indicates that the sewage test “is a very good early warning system,” as reported by “CNN.”
A new direction for understanding the virus
In a parallel vein, a group of researchers at Oak Ridge National Laboratory in Tennessee used the Summit supercomputer, the world’s second-fastest computer, to analyze data on more than 40,000 genes out of 17,000. A genetic sample associated with the SARS-Cove-2 virus. The analysis took more than a week and examined 2.5 billion gene pools. The researchers came up with a new hypothesis, called the “bradykinin” hypothesis, about how the “Covid-19” disease affects the human body.
Before that, it was known that the “SARS-Cove-2” virus enters the human cell through its crowns which penetrate the enzyme “ACE2”, which is found in abundance in the lung, as well as in the intestine, kidneys and heart. However, how mucus fluid accumulates in the lung and the reason for this is unknown. And this made the oxygen saturation level in the blood of the patients low, and they became prisoners of respirators. According to recent analysis, the researchers revealed that in the “quinine” system (a hormonal system made up of blood proteins that play a role in controlling inflammation and blood pressure, clotting, and pain), bradykinin, a peptide (a short chain of amino acids) primarily causes blood vessels to leak, allowing fluid to accumulate in organs and tissues. In patients with “Covid-19”, this system was “unbalanced”.
Research indicates that there are already medications that are licensed and approved by the US Food and Drug Administration (FDA) capable of treating this problem. However, “testing any of these therapeutic interventions through drugs must be done in well-designed clinical trials, before they begin to be prescribed to patients,” according to the researchers.
